F-18 Flurpiridaz Cardiac PET Perfusion Imaging

Introduction

Flurpiridaz F-18 is the first fluorine-18 PET myocardial perfusion tracer approved in the United States, and its physics is the reason it matters. A roughly 110-minute half-life lets facilities buy unit doses from a regional PET pharmacy instead of running an on-site generator or cyclotron, makes genuine exercise stress practical, and — because fluorine-18 emits low-energy positrons — delivers sharper images and supports absolute myocardial blood flow quantification. ^{1, 2, 6}

For decades, PET myocardial perfusion imaging (MPI) has been limited by its tracers rather than by the technology. Rubidium-82 requires an expensive strontium-82/rubidium-82 generator at the bedside and its very short half-life confines it to pharmacologic stress. Nitrogen-13 ammonia needs an on-site cyclotron. Both constraints kept PET MPI concentrated at large centers even as the evidence for its accuracy grew. Flurpiridaz F-18 (brand name FLYRCADO), approved by the FDA in September 2024, changes the logistics: a fluorine-18 label with a two-hour half-life can be shipped, and that single physical property reshapes who can offer cardiac PET. ^{1, 3, 5}

This guide explains the underlying physics — half-life, positron energy, and extraction — that make flurpiridaz distinctive, the phase 3 evidence behind its approval, its dosimetry, and the quality-control and regulatory context a facility should understand before adopting it. DRPS supports nuclear cardiology programs through its PET/CT and nuclear medicine physics and medical physics consulting services across Florida, Maryland, Virginia, Washington DC, California, Nevada, and beyond.

Topic Explanation

What is flurpiridaz F-18?

Flurpiridaz F-18 is a fluorine-18-labeled small molecule that binds mitochondrial complex I (MC-1) in heart muscle, producing a PET perfusion image proportional to myocardial blood flow. Because uptake tracks blood flow with high first-pass extraction, regions supplied by a stenosed coronary artery show reduced tracer during stress relative to rest — the hallmark of inducible ischemia. ^{2, 7}

Key facts about the agent:

It is indicated for PET MPI under rest or stress (pharmacologic or exercise) in adults with known or suspected coronary artery disease (CAD), to evaluate for myocardial ischemia and infarction. ¹
It was approved by the FDA in September 2024 and is the first F-18 PET perfusion tracer approved in the United States. ^{3, 5}
It is administered intravenously, at rest and again during stress. ¹

For facilities already familiar with PET perfusion, flurpiridaz slots into the same interpretive framework as our overview of rubidium-82 cardiac PET MPI and quantitative myocardial blood flow with cardiac PET, but its logistics and physics differ in ways that change practice.

Why the tracer's physics drives the clinical value

The clinical advantages of flurpiridaz are downstream of two physical properties: a long half-life and a low positron energy. The half-life governs logistics and stress options; the positron energy governs image sharpness. Together with high myocardial extraction, they explain why phase 3 studies found flurpiridaz PET outperformed SPECT, especially in women and obese patients where SPECT struggles with attenuation and count statistics. ^{6, 7}

That is the throughline of this article: flurpiridaz is not a better tracer because of marketing — it is a better tracer because fluorine-18's decay characteristics are well suited to cardiac imaging, and because the molecule is extracted and retained by myocardium in proportion to flow. ^{2, 6}

Key Technical Principles

Half-life, logistics, and stress

Fluorine-18 decays by positron emission with a physical half-life of about 109.8 minutes. ⁹ That is the single most consequential number for a cardiac PET program, and its effect is easiest to see through decay math.

Radioactive decay follows:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}}

For fluorine-18, $λ = ln 2/109.8 min = 0.00631 min^{- 1}$ . The fraction of activity remaining two hours (120 minutes) after calibration is:

\frac{A ( 120 )}{A _{0}} = e^{- 0.00631 \times 120} \approx e^{- 0.758} \approx 0.47

So about 47% of the delivered activity is still present two hours later — enough to ship a unit dose from a regional PET pharmacy and use it clinically. Contrast rubidium-82, with a half-life of about 76 seconds (1.27 minutes). After just five minutes:

\frac{A ( 5 )}{A _{0}} = e^{- (l n 2/1.27) \times 5} \approx e^{- 2.73} \approx 0.065

Only about 6.5% remains after five minutes, which is why rubidium-82 must be eluted from a generator at the patient's side and can only be used with pharmacologic stress. Nitrogen-13 ammonia, with a roughly 10-minute half-life, needs an on-site cyclotron. Flurpiridaz's two-hour half-life removes both constraints and, crucially, gives the tracer time to survive the interval between injection at peak treadmill or bicycle exercise and image acquisition — making true exercise stress feasible in PET for the first time in routine practice. ^{2, 6}

Positron energy and spatial resolution

The spatial resolution of any PET tracer is fundamentally limited by positron range — the distance a positron travels before it annihilates and produces the two 511 keV photons the scanner detects. Higher positron energy means a longer range and blurrier images. This is where flurpiridaz has a physical advantage. ^{7, 12}

Tracer	Physical half-life	Production / supply	Maximum positron energy	Stress compatibility
Rubidium-82	~76 seconds	Sr-82/Rb-82 generator (on-site)	~3.4 MeV	Pharmacologic only
N-13 ammonia	~10 minutes	On-site cyclotron	~1.2 MeV	Pharmacologic (exercise impractical)
Flurpiridaz F-18	~110 minutes	Cyclotron + regional unit-dose delivery	~0.63 MeV	Exercise or pharmacologic

Fluorine-18 emits the lowest-energy positrons of the three, with a maximum energy of about 0.63 MeV, compared with roughly 1.2 MeV for N-13 and up to about 3.4 MeV for Rb-82. ^{9, 12} The shorter positron range that results translates into better intrinsic spatial resolution — a meaningful advantage for resolving small perfusion defects and thin myocardial walls. This resolution benefit, combined with high first-pass extraction that keeps tracer uptake closely proportional to flow even at high flow rates, is central to flurpiridaz's image quality and to reliable absolute myocardial blood flow quantification. ^{2, 6, 7}

Myocardial extraction and blood flow quantification

A perfusion tracer is only as good as the relationship between its uptake and true myocardial blood flow. Tracers with low extraction "roll off" at high flow — uptake plateaus even as flow keeps rising, so the image underestimates hyperemic flow. Flurpiridaz has favorable, high first-pass myocardial extraction that stays more linear with flow than older agents, which improves both visual defect contrast and the accuracy of quantitative myocardial blood flow and coronary flow reserve. ^{2, 7}

Absolute flow quantification — reporting stress and rest myocardial blood flow in mL/min/g and their ratio — is one of the defining strengths of PET over SPECT, and the ASNC/SNMMI procedure standard for PET nuclear cardiology describes the dynamic acquisition and kinetic modeling required to obtain it. Flurpiridaz's kinetics make it well suited to this workflow. ^{7, 8}

Clinical Impact

Flurpiridaz's phase 3 evidence is what turned its favorable physics into an approval. In the second phase 3 multicenter trial of patients with suspected CAD, flurpiridaz PET had significantly higher sensitivity than Tc-99m SPECT (80.3% versus 68.7%) with noninferior specificity (63.8% versus 61.7%), and a higher area under the receiver-operating-characteristic curve (0.80 versus 0.68). The advantages were pronounced in women and in obese patients — precisely the groups in whom SPECT is most degraded by attenuation and limited count statistics. Flurpiridaz PET was also superior for perfusion defect size and severity, image quality, diagnostic certainty, and radiation exposure, and it was safe and well tolerated. ⁶

The practical implications for a nuclear cardiology program are several:

Broader access to PET MPI. Unit-dose delivery means centers without a generator or cyclotron can offer cardiac PET, expanding a modality previously concentrated at large institutions. ^{2, 3}
Exercise stress in PET. For patients who can exercise, treadmill or bicycle stress adds functional information (exercise capacity, symptoms, hemodynamic response) that pharmacologic stress cannot, and flurpiridaz makes it feasible. ^{2, 6}
Better performance where SPECT is weakest. Improved accuracy in women and obese patients addresses a long-standing gap. ⁶
Quantitative flow. Reliable myocardial blood flow and flow reserve support evaluation of balanced ischemia and microvascular disease. ⁷

These strengths do not make flurpiridaz automatic for every facility. The scanner must support the dynamic, list-mode acquisition that flow quantification requires, and staff must be trained in both PET perfusion interpretation and exercise-stress-in-PET logistics. The infrastructure and QC that support any PET perfusion program — described in our guides to PET/CT daily QC and calibration and PET/CT NEMA NU-2 performance testing — apply directly. ^{7, 8}

Practical Optimization Tips

Adopting flurpiridaz is as much an operations and physics exercise as a clinical one.

1. Verify dose-calibrator setup for F-18

Assay every unit dose in a dose calibrator with a calibration traceable to a national standard, using the correct F-18 setting. Confirm the calibrator's F-18 response during acceptance and routine QC; an incorrect setting biases every administered activity. This ties directly to the facility's dose calibrator quality control program.

2. Match the acquisition to quantification goals

If the program intends to report absolute myocardial blood flow, the scanner must acquire dynamic list-mode data from the time of injection, and the reconstruction and kinetic-modeling software must be validated for flurpiridaz. Confirm the vendor's flow-quantification pathway before promising quantitative reports. ^{7, 8}

3. Plan the stress workflow deliberately

Exercise stress in PET requires the patient to be injected at peak stress and then positioned in the scanner. Because flurpiridaz's half-life tolerates the delay, build a workflow that manages the transfer, uptake, and imaging window consistently, and standardize it so studies are reproducible. ^{2, 6}

4. Use the correct administered activity

Follow the prescribing information: same-day rest 93–111 MBq (2.5–3 mCi), pharmacologic stress 222–241 MBq (6–6.5 mCi), exercise stress 333–352 MBq (9–9.5 mCi); two-day protocol 93–111 MBq for each acquisition. Document the activity delivered for each study. ¹

5. Manage the patient as a 511 keV source

Like all PET, the injected patient is a source of highly penetrating 511 keV annihilation photons. Uptake-room placement, time-and-distance discipline, and hot-lab handling all apply, consistent with the facility's radiation-protection program and shielding design.

Common pitfalls to avoid

Assuming any PET scanner can quantify flow. Absolute blood flow needs dynamic list-mode acquisition and validated modeling.
Copying a rubidium-82 workflow verbatim. Flurpiridaz's half-life enables exercise stress and unit-dose logistics that Rb-82 does not.
Neglecting dose-calibrator F-18 QC. A wrong setting biases every administered activity.
Underestimating training. Exercise-stress PET and quantitative interpretation both require deliberate staff preparation.
Forgetting the CT dose. In PET/CT, the attenuation-correction and any diagnostic CT contribute dose that must be optimized separately.

Regulatory Considerations

Flurpiridaz F-18 is byproduct material, so its medical use falls under NRC or Agreement State regulation, and its administration requires an appropriately authorized user and a compliant radiation safety program. The relevant frameworks are the same ones that govern any unsealed PET radiopharmaceutical. ^{10, 11}

Key regulatory anchors:

10 CFR Part 35 — Medical Use of Byproduct Material. Governs authorized users, dose-calibrator and instrument requirements, and the radiation safety program for unsealed byproduct material used in imaging. ¹⁰
10 CFR Part 20 — Standards for Protection Against Radiation. Sets occupational and public dose limits that shape hot-lab handling, uptake-room design, and patient-flow decisions. ¹¹
FDA prescribing information. The FLYRCADO label defines the approved indication, administered activities, and administration and safety requirements, including that pharmacologic or exercise stress be performed where resuscitation equipment and trained staff are available. ¹
ASNC/SNMMI PET nuclear cardiology procedure standard. Describes acquisition, quality control, and quantification expectations for PET MPI that a defensible program should follow. ⁸

Jurisdiction depends on the state. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license the medical use of byproduct material under their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its materials license and add flurpiridaz to the license — with an authorized user and appropriate training — before administering it. Programs pursuing or maintaining accreditation should also align with accreditation support requirements for nuclear cardiology.

Frequently Asked Questions (FAQs)

What is flurpiridaz F-18?

Flurpiridaz F-18 (brand name FLYRCADO) is a fluorine-18-labeled PET myocardial perfusion imaging agent approved by the FDA in September 2024 for evaluating myocardial ischemia and infarction in adults with known or suspected coronary artery disease. It binds mitochondrial complex I in cardiac muscle and is the first F-18 PET perfusion tracer approved in the United States.

Why does the 110-minute half-life of flurpiridaz matter?

Fluorine-18 has a physical half-life of about 110 minutes, far longer than rubidium-82 (about 76 seconds) or nitrogen-13 ammonia (about 10 minutes). That longer half-life lets a facility receive unit doses from a regional PET pharmacy instead of needing an on-site generator or cyclotron, and it makes true treadmill or bicycle exercise stress practical because the tracer survives the time between injection at peak stress and imaging.

How does flurpiridaz compare with rubidium-82 and N-13 ammonia for image quality?

Flurpiridaz emits relatively low-energy positrons (maximum about 0.63 MeV) compared with rubidium-82 (up to about 3.4 MeV) and N-13 ammonia (about 1.2 MeV). Lower positron energy means a shorter positron range before annihilation, which improves intrinsic spatial resolution. Combined with high first-pass myocardial extraction, this supports sharp images and reliable absolute myocardial blood flow quantification.

What is the radiation dose from a flurpiridaz PET study?

Published dosimetry reports a mean effective dose of about 0.015 mSv/MBq with exercise stress and about 0.019 mSv/MBq with adenosine pharmacologic stress. With typical administered activities, a combined rest and stress study delivers a few millisieverts, and phase 3 data found flurpiridaz PET delivered lower radiation exposure than the comparator SPECT study.

What administered activity is used for flurpiridaz?

Per the FDA prescribing information, a same-day protocol uses about 93 to 111 MBq (2.5 to 3 mCi) at rest, 222 to 241 MBq (6 to 6.5 mCi) for pharmacologic stress, and 333 to 352 MBq (9 to 9.5 mCi) for exercise stress. A two-day protocol uses about 93 to 111 MBq for both the rest and the stress acquisitions.

What did the phase 3 trials show for flurpiridaz?

In the second phase 3 trial, flurpiridaz PET had higher sensitivity than SPECT (80.3% versus 68.7%) with noninferior specificity, and a higher area under the ROC curve (0.80 versus 0.68), with particular advantages in women and obese patients. It was also superior to SPECT for defect assessment, image quality, diagnostic certainty, and radiation exposure, and was safe and well tolerated.

Key Takeaways

Flurpiridaz F-18 is the first F-18 PET perfusion tracer approved in the U.S. (September 2024), binding mitochondrial complex I in myocardium in proportion to blood flow.
The ~110-minute half-life is the key logistics enabler — unit-dose delivery from a regional PET pharmacy and, for the first time in routine PET, feasible exercise stress.
Low positron energy (~0.63 MeV) sharpens images. A shorter positron range improves intrinsic spatial resolution relative to Rb-82 and N-13 ammonia.
High first-pass extraction supports quantification. Uptake stays closer to linear with flow, aiding absolute myocardial blood flow and flow reserve.
Phase 3 data favored PET over SPECT, especially in women and obese patients, with lower radiation exposure.
It is byproduct material. Medical use requires an authorized user, license amendment, dose-calibrator QC, and a Part 20/Part 35-compliant program.

Conclusion

Flurpiridaz F-18 is a case study in how tracer physics drives clinical capability. A two-hour half-life turns a bedside-generator modality into a shippable one and makes exercise stress possible in PET; a low positron energy tightens spatial resolution; and high, flow-linear myocardial extraction makes both the pictures and the numbers more trustworthy. The phase 3 evidence — higher sensitivity than SPECT, better performance in women and obese patients, and lower radiation exposure — followed from those properties rather than in spite of them.

For a nuclear cardiology program, the opportunity is real but not turnkey. Realizing flurpiridaz's advantages requires a scanner and software capable of dynamic, quantitative acquisition, a deliberately designed exercise-stress workflow, rigorous dose-calibrator and PET QC, and a license and authorized-user structure that permits its use. Facilities that treat adoption as a coordinated physics, operations, and regulatory project — not just a new order code — will capture the benefit that the tracer's physics makes available.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear cardiology and PET/CT programs adopting flurpiridaz and other PET perfusion agents with scanner acceptance and NEMA performance testing, dose-calibrator and instrument QC, quantification-pathway validation, radiation safety and shielding review, license-amendment support, and accreditation readiness — all delivered by board-certified medical physicists. Explore our PET/CT and nuclear medicine physics, medical physics consulting, and accreditation support services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A new tracer is only as good as the program around it. The physics is the opportunity; the QC and workflow are how you realize it.

Related Resources

References

U.S. Food and Drug Administration. FLYRCADO (flurpiridaz F 18) injection — Highlights of Prescribing Information. 2024. accessdata.fda.gov
Patel KK, Singh A, Bateman TM. The Potential of F-18 Flurpiridaz PET/CT Myocardial Perfusion Imaging for Precision Imaging. Curr Cardiol Rep. 2022;24(8):987-994. doi:10.1007/s11886-022-01713-5. PubMed
U.S. Food and Drug Administration. FDA Approves Imaging Drug for Evaluation of Myocardial Ischemia and Infarction. 2024. fda.gov
Maddahi J, Bengel F, Czernin J, et al. Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. J Nucl Cardiol. 2019;26(6):2018-2030. doi:10.1007/s12350-018-01484-z. PubMed
Keam SJ. Flurpiridaz F 18: First Approval. Am J Cardiovasc Drugs. 2025;25(1):1-6. doi:10.1007/s40256-024-00718-5. PubMed
Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. J Am Coll Cardiol. 2023;82(16):1598-1610. doi:10.1016/j.jacc.2023.08.016. PubMed
Liga R, Neglia D. Emerging F-18-Labelled PET Myocardial Perfusion Tracers. Curr Cardiol Rep. 2020;22(10):116. doi:10.1007/s11886-020-01368-0. PubMed
Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23(5):1187-1226. doi:10.1007/s12350-016-0522-3. PubMed
Bergeron DE, Fitzgerald R, et al. (National Institute of Standards and Technology). A Review of NIST Primary Activity Standards for 18F. J Res Natl Inst Stand Technol. 2014;119:13. nist.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org